1. Clinical & Scientific Overview
Levofloxacin Hemihydrate (TIP-MED-000137, Reference Code [8.9]) is classified under
Antimicrobials — Antibacterial & Antibiotic Agents (Ch 08) as a Third-Generation ('Respiratory') Fluoroquinolone Antibiotic (L-Isomer of Ofloxacin; Bactericidal; WHO 'Watch' Group).
Within the Indian regulatory and compendial framework, it is governed under Schedule H1 Prescription Drug (Mandatory Red-Bordered Rx Warning & 3-Year Register under Rule 65 of Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 08 [8.9], p. 97): Levoflox (Cipla), Glevo (Glenmark), Levomac (Macleods), Tavanic (Sanofi), L-Cin (Lupin), Fynal — Strengths & Dosage Forms: Oral Film-Coated Tablets: 250 mg, 500 mg, 750 mg; IV Infusion: 500 mg/100 mL
Oral Film-Coated Tablets: 250 mg, 500 mg, 750 mg; IV Infusion: 500 mg/100 mL
3. Mechanism of Action & Pharmacodynamics
Third-Generation ('Respiratory') Fluoroquinolone Antibiotic (L-Isomer of Ofloxacin; Bactericidal; WHO 'Watch' Group) acting on target receptor/enzyme pathways in Antimicrobials — Antibacterial & Antibiotic Agents (Ch 08): clinical efficacy is mediated via Third-Generation ('Respiratory') Fluoroquinolone Antibiotic (L-Isomer of Ofloxacin; Bactericidal; WHO 'Watch' Group) for Community-acquired pneumonia (with enhanced Streptococcus pneumoniae and atypical pathogen coverage compared to ciprofloxacin), complicated urinary tract infections and acute pyelonephritis, chronic bacterial prostatitis, complicated skin/soft-tissue infections, and second-line multidrug-resistant tuberculosis (MDR-TB) regimens. (Never use empirically in patients with cough >2 weeks before ruling out Pulmonary TB!)..
4. Therapeutic Indications & Evidence-Supported Uses
- Community-acquired pneumonia (with enhanced Streptococcus pneumoniae and atypical pathogen coverage compared to ciprofloxacin), complicated urinary tract infections and acute pyelonephritis, chronic bacterial prostatitis, complicated skin/soft-tissue infections, and second-line multidrug-resistant tuberculosis (MDR-TB) regimens
- (Never use empirically in patients with cough >2 weeks before ruling out Pulmonary TB!)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: 500 mg once daily for 7–14 days (or 750 mg once daily for 5 days in CAP/acute pyelonephritis/sinusitis; 250 mg once daily for 3 days in uncomplicated UTI). Dosing strictly depends on renal CrCl! Follow physician prescription.
Administration & Meal Timing: With or without food (unlike ciprofloxacin, ordinary milk/meals do not substantially impair levofloxacin absorption, HOWEVER polyvalent metal cations [Calcium, Iron, Zinc, Magnesium/Aluminium Antacids, Sucralfate] STILL chelate and block levofloxacin absorption!). | Once daily in the morning (morning dosing reduces fluoroquinolone-induced nocturnal insomnia and vivid dreams).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: STRICTLY RENAL-FUNCTION DEPENDENT (Excreted >85% unchanged in urine—even more renally dependent than ciprofloxacin)! • CrCl ≥50 mL/min: Standard dose (500 mg or 750 mg every 24 h). • CrCl 20–49 mL/min: For 500 mg regimen -> 500 mg initial dose on Day 1, then 250 mg once every 24 hours (For 750 mg regimen -> 750 mg once every 48 hours). • CrCl 10–19 mL/min or Dialysis: For 500 mg regimen -> 500 mg initial dose on Day 1, then 125 mg–250 mg once every 48 hours! Hepatic: No hepatic metabolism; no adjustment required.
Renal: STRICTLY RENAL-FUNCTION DEPENDENT (Excreted >85% unchanged in urine—even more renally dependent than ciprofloxacin)! • CrCl ≥50 mL/min: Standard dose (500 mg or 750 mg every 24 h). • CrCl 20–49 mL/min: For 500 mg regimen -> 500 mg initial dose on Day 1, then 250 mg once every 24 hours (For 750 mg regimen -> 750 mg once every 48 hours). • CrCl 10–19 mL/min or Dialysis: For 500 mg regimen -> 500 mg initial dose on Day 1, then 125 mg–250 mg once every 48 hours! Hepatic: No hepatic metabolism; no adjustment required.
Renal: STRICTLY RENAL-FUNCTION DEPENDENT (Excreted >85% unchanged in urine—even more renally dependent than ciprofloxacin)! • CrCl ≥50 mL/min: Standard dose (500 mg or 750 mg every 24 h). • CrCl 20–49 mL/min: For 500 mg regimen -> 500 mg initial dose on Day 1, then 250 mg once every 24 hours (For 750 mg regimen -> 750 mg once every 48 hours). • CrCl 10–19 mL/min or Dialysis: For 500 mg regimen -> 500 mg initial dose on Day 1, then 125 mg–250 mg once every 48 hours! Hepatic: No hepatic metabolism; no adjustment required.
7. Contraindications, Precautions & High-Risk Warnings
- Same Class Boxed Warnings as Ciprofloxacin: Achilles tendinitis and tendon rupture (especially >60 years or with corticosteroids), peripheral neuropathy, CNS toxicity (delirium, hallucinations, seizures), aortic aneurysm/dissection, myasthenia gravis exacerbation, QTc prolongation, and severe dysglycaemia.
Key Clinical Precautions: Renal: STRICTLY RENAL-FUNCTION DEPENDENT (Excreted >85% unchanged in urine—even more renally dependent than ciprofloxacin)! • CrCl ≥50 mL/min: Standard dose (500 mg or 750 mg every 24 h). • CrCl 20–49 mL/min: For 500 mg regimen -> 500 mg initial dose on Day 1, then 250 mg once every 24 hours (For 750 mg regimen -> 750 mg once every 48 hours). • CrCl 10–19 mL/min or Dialysis: For 500 mg regimen -> 500 mg initial dose on Day 1, then 125 mg–250 mg once every 48 hours! Hepatic: No hepatic metabolism; no adjustment required.
8. Adverse Effects Profile
- Nausea, diarrhoea, headache, insomnia, dizziness, photosensitivity.
- Tendon rupture, severe hypoglycaemia (and hyperglycaemic coma) in elderly diabetics, QTc interval prolongation / torsades de pointes, acute delirium/psychosis in the elderly, C. difficile colitis, hepatotoxicity.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Chelation Blockade: Separate from Calcium, Iron, Zinc, Multivitamins, Antacids, and Sucralfate by at least 2 hours before or 2–4 hours after! (Note: Unlike ciprofloxacin, levofloxacin does NOT inhibit CYP1A2, so it does not interact with theophylline, tizanidine, or caffeine!)
- However, it has strong additive QTc prolongation with Amiodarone, Sotalol, Domperidone, Ondansetron, Azithromycin, and Escitalopram; potentiates Warfarin INR; causes severe hypoglycaemia with Sulfonylureas and Insulin; and increases seizure risk with NSAIDs
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Take once daily in the morning, spaced at least 2 hours away from any Calcium, Iron, Zinc, or Antacid medicine. Stop immediately and inform the doctor if heel/calf tendon pain, numbness/tingling in hands/feet, confusion, or low blood sugar sweats occur. Protect skin from harsh sunlight.
- Meal & Clock Timing Instruction: With or without food (unlike ciprofloxacin, ordinary milk/meals do not substantially impair levofloxacin absorption, HOWEVER polyvalent metal cations [Calcium, Iron, Zinc, Magnesium/Aluminium Antacids, Sucralfate] STILL chelate and block levofloxacin absorption!). (Once daily in the morning (morning dosing reduces fluoroquinolone-induced nocturnal insomnia and vivid dreams).)
- Missed Dose Protocol: Take as soon as remembered on the same day (spaced 2 hours from calcium/iron); never double.
- Geriatric Dispensing Pearl: Because >85% of levofloxacin is cleared unchanged by the kidneys, giving standard 500 mg or 750 mg daily to an 80-year-old CGHS patient with CrCl 25–40 mL/min causes rapid CNS accumulation (presenting as acute agitation, visual hallucinations, or seizures), Achilles tendon rupture (especially if co-prescribed Prednisolone for COPD!), and severe hypoglycaemia.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Film-Coated Tablets: 250 mg, 500 mg, 750 mg; IV Infusion: 500 mg/100 mL
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 08 [8.9] (p. 97)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [8.24] Moxifloxacin & Ofloxacin — Fourth- & Second-Generation Fluoroquinolone DNA Gyrase / Topoisom
- [8.25] Co-trimoxazole (Trimethoprim + Sulfamethoxazole — TMP-SMX) — Synergistic Sequential Folate Pathway Inhibitor — DHFR + DHPS Blo
- [8.26] Fosfomycin Trometamol — Phosphonic Acid Epoxide Cell-Wall (MurA) Synthesis Inhibitor — Si
- [8.27] Vancomycin & Teicoplanin (Glycopeptide Reserve Antibiotics) — Glycopeptide Cell-Wall D-Ala-D-Ala Peptidoglycan Inhibitors — ICM